Genentech, a member of the Roche Group (ROG.SW,RO.SW), announced the U.S. FDA approved TECENTRIQ (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
"TECENTRIQ is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy. TECENTRIQ is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works," said Sandra Horning, chief medical officer and head of Global Product Development.
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
5 Sets of Economic Data Points That Matter for the Week
11 People Who Walked Away With Nobel Prizes of 2016
Riches to Rags: Billionaires Who Lost It All
0 Response to "Genentech: FDA Approves TECENTRIQ To Treat Type Of Metastatic Lung Cancer - RTT News"
Post a Comment